Evidence map›Paper›PMID 20039422›Full record

ArticleArthritis and rheumatism2010

Good and bad memories following rituximab therapy.

E William St Clair

Abstract readEditorialComment
In one paragraph

Article in Arthritis and rheumatism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Rituximab for people with multiple sclerosis.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Rituximab for people with multiple sclerosis.The Cochrane database of systematic reviews · 2021
    Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

E William St Clair

Funding

Supplement - Inflammatory Triggers in B Cell AutoimmunityU19AI056363 · NIAID · DUKE UNIVERSITY · PI ST. CLAIR, EUGENE WILLIAM · 2003 to 2017
$35.3M
IMMUNE TOLERANCE NETWORK-266015416-266015416N01AI015416 · NIAID · REGENTS OF THE UNIVERSITY OF C · PI BLUESTONE, JEFFREY A · 2002 to 2006
–
NIAID NIH HHS AI-056363NIAID NIH HHS AI-15416NIAID NIH HHS N01 AI015416NIAID NIH HHS U19 AI056363
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antirheumatic AgentsArthritis, RheumatoidB-Lymphocyte SubsetsHemocyaninsHumansImmunity, CellularImmunologic MemoryInfluenza VaccinesLymphocyte DepletionPneumococcal VaccinesRituximabTetanus ToxoidAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antirheumatic AgentsHemocyaninsInfluenza Vaccineskeyhole-limpet hemocyaninPneumococcal VaccinesRituximabTetanus Toxoid

Identifiers

PMID20039422
PMCPMC2806494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.